Please use this identifier to cite or link to this item:
Title: Review article: controversies surrounding the use of carvedilol and other beta blockers in the management of portal hypertension and cirrhosis.
Austin Authors: Gillespie, Sarah-Louise;Hanrahan, Timothy P;Rockey, Don C;Majumdar, Avik;Hayes, Peter C
Affiliation: Centre for Liver and Digestive Disorders, Royal Infirmary of Edinburgh, Edinburgh, UK.
Digestive Disease Research Center, Medical University of South Carolina, Charleston, South Carolina, USA.
Gastroenterology and Hepatology
Issue Date: Mar-2023
Date: 2023
Publication information: Alimentary Pharmacology & Therapeutics 2023; 57(5)
Abstract: Advanced chronic liver disease is an increasing cause of premature morbidity and mortality in the UK. Portal hypertension is the primary driver of decompensation, including the development of ascites, hepatic encephalopathy and variceal haemorrhage. Non-selective beta blockers (NSBB) reduce portal pressure and are well established in the prevention of variceal haemorrhage. Carvedilol, a newer NSBB, is more effective at reducing portal pressure due to additional α-adrenergic blockade and has additional anti-oxidant, anti-inflammatory and anti-fibrotic effects.
DOI: 10.1111/apt.17380
ORCID: 0000-0002-1476-9369
Journal: Alimentary Pharmacology & Therapeutics
PubMed URL: 36691947
ISSN: 1365-2036
Type: Journal Article
Subjects: Clinical Pharmacology
portal hypertension
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on May 27, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.